BIIB Stock Ends 3% Higher - Why This Strategist Picks Biogen Over Other Biotech Peers

(MENAFN - AsiaNet News) Woods noted that Biogen has multiple focuses across autoimmune kidney diseases and Alzheimer's, unlike many names in the sector, which rely on a specific drug ...